Gurobi 11.0 Delivers Global Nonlinear Solving, Speed Enhancements, Dynamic Distributed Tuning, and Enterprise Features
Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced the release of Gurobi Optimizer 11.0. This advancement marks a significant step forward in solving real-world nonlinear problems with Gurobi.
With Gurobi 11.0, users can quickly identify precise, globally optimal solutions to complex nonlinear problems—from domains such as chemical engineering, electricity flow, and price optimization. Additionally, this new version delivers a key enhancement to Gurobi’s popular tuning tool, enabling teams to share resources across multiple users and jobs when tuning.
As with every major Gurobi release, users will experience a boost to Gurobi’s industry-leading solver speed. Compared to Gurobi 10.0, version 11.0 delivers the following performance improvements:
|
Algorithm |
Speed-Up:
|
Speed-Up:
|
|
MILP |
8.6% |
12.4% |
|
MIQP |
12.8% |
22.8% |
|
Convex MIQCP |
9.2% |
18.2% |
|
Nonconvex MIQCP |
133.4% (2.3x) |
480.2% (5.8x) |
“For nonconvex problems, we achieved several key milestones, including being able to solve MINLPs to global optimality and achieving a 5.8x speed-up on nonconvex MIQCP,” said Dr. Tobias Achterberg, Vice President of Research and Development at Gurobi Optimization.
What’s New in Gurobi 11.0
In addition to speed enhancements, Gurobi 11.0 includes a full suite of new features, many of which are based specifically on user requests.
Gurobi Optimizer
- Mixed-Integer Nonlinear Programming (MINLP) Problems: Quickly identify precise, globally optimal solutions to complex nonlinear problems.
- Dynamic Distributed Tuning: With this key enhancement to Gurobi’s popular tuning tool, teams can now share resources across multiple users and jobs when tuning.
- Improved Concurrent LP Controls: For both deterministic and non-deterministic LP, users can now select precisely which algorithms should be run in a concurrent fashion.
- New SolutionTarget Option: A new SolutionTarget setting allows users who do not need an optimal basis to obtain faster solutions to LP problems.
Gurobi Cluster Manager and Compute Server
- SAML Integration: Users can now enjoy centralized user access management and single sign-on (SSO) capabilities through Gurobi’s seamless integration with SAML-based identity management systems, in addition to existing support for LDAP.
- Cosmos DB Support: Gurobi now supports Microsoft® Azure® Cosmos DB®, in addition to existing support for MongoDB® and Amazon® DocumentDB®, for enhanced flexibility when deploying compute clusters.
- Usability Enhancements: The Gurobi Cluster Manager delivers a new look-and-feel and now offers username case sensitivity controls, improved date formatting, and support for the latest HTTP security headers.
- Time and Memory Limit Enforcement: Gurobi Compute Server includes new parameters for enforcing time and memory limits.
“Our new global nonlinear solving capabilities will make a big impact for customers,” explained Duke Perrucci, Gurobi’s Chief Executive Officer. “Rather than settling for best-guess solutions, customers will be able to quickly identify precise, globally optimal solutions. This can translate into major cost efficiencies for organizations.”
Michel Jacyznski, Gurobi Senior Director of Cloud and Platform R&D, added, “With the addition of the SAML 2.0 authentication and the support of the CosmosDB database, we continue to demonstrate our dedication to seamless enterprise integration while providing a modern and user-friendly environment to deploy the Gurobi Optimizer.”
Gurobi will be hosting a webinar to discuss these new capabilities and how customers can put them into practice. To learn more about this upcoming event, visit gurobi.com/events.
About Gurobi Optimization
With Gurobi’s decision intelligence technology, customers can make optimal business decisions in seconds. From workforce scheduling and portfolio optimization to supply chain design and everything in between, Gurobi identifies your optimal solution, out of trillions of possibilities.
As the leader in decision intelligence, Gurobi delivers easy-to-integrate, full-featured software and best-in-class support, with an industry-leading 98% customer satisfaction rating.
Founded in 2008, Gurobi has operations across the Americas, Europe, and Asia. Over 2,500 global customers across 40+ industries run on Gurobi, including SAP, Air France, and the National Football League, as well as over 80% of the world’s leading enterprises. For more information, please visit https://www.gurobi.com/ or call +1 713 871 9341.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231204907837/en/
Contact information
Nell-Marie Colman
(540) 952 9719
Gurobi Optimization
colman@gurobi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Access Advance Announces Major Growth in Its HEVC and VVC Patent Pools24.11.2025 17:10:00 EET | Press release
Access Advance LLC today announced significant expansions of both its HEVC Advance and VVC Advance Patent Pools during the second and third quarters of 2025, underscoring continued industry confidence in the company's balanced and transparent approach to video codec licensing. This growth follows the successful January 2025 launch of Access Advance's Video Distribution Patent ("VDP") Pool, demonstrating the company's expanding role in comprehensive video codec patent licensing solutions. Among the many highlights, Sharp Corporation joined the HEVC Advance Patent Pool as a Licensor, bringing valuable intellectual property assets to the pool's already extensive patent portfolio. Additionally, Huawei Technologies Co., Ltd., already an HEVC Advance Licensor and Licensee, expanded its collaboration with Access Advance by joining the VVC Advance Patent Pool as a Licensee. HP Inc. also expanded its license to include the VVC Advance Patent Pool after previously joining HEVC Advance in 2024, w
Andersen Global Strengthens Platform in Turkey with Addition of Member Firm24.11.2025 16:30:00 EET | Press release
Andersen Global enhances its presence in Turkey as Celen Corporate Property Valuation & Counseling Inc. becomes Andersen in Turkey, adding breadth to the capabilities provided under the Andersen brand in the country. Founded in 1995 and led by Managing Partner Guniz Celen, the Istanbul-based firm delivers a broad spectrum of services for domestic and international clients. With expertise in real estate corporate finance, tangible and intangible asset valuation, and asset management, Andersen in Turkey delivers solutions that support complex corporate finance decisions to clients in more than 18 countries. “Our mission has always been to provide solutions to the most complex challenges in the real estate and investment sectors,” said Guniz. “Joining the Andersen brand strengthens our capabilities as a trusted advisor and gives us access to global resources, enabling us to create even greater long-term value for our clients.” Global Chairman and CEO of Andersen Mark L. Vorsatz added, “Ce
Microsize and Schedio Group to Acquire Lonza’s Micro-Macinazione Site in Switzerland24.11.2025 16:05:00 EET | Press release
Microsize, a leading CDMO specializing in particle size reduction and control technologies, today announced it has signed an agreement to acquire Micro-Macinazione (Mic Mac), a dedicated micronization facility in Monteggio, Switzerland, from Lonza. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251124545344/en/ The agreement represents Microsize’s second acquisition from Lonza, following the successful 2022 divestment of its Quakertown, Pennsylvania site. In this transaction, Schedio Group – a Swiss-based provider of jet mills, isolators, spray dryers, and engineering services – is investing alongside Microsize to strengthen and localize its operational base in Europe, advancing a shared vision to lead the next generation of integrated particle engineering solutions. With more than 30 years of experience, Mic Mac has served the pharmaceutical industry with proven GMP-compliant jet milling and micronization capabilities for b
Hytera to Debut S1 E at PMRExpo 202524.11.2025 15:17:00 EET | Press release
Hytera, a leading global provider of critical communications technologies and solutions, today introduced the S1 E, a business-ready, palm-sized two-way radio designed specifically for the retail sector, expanding the portfolio of S Series and providing one more option for retail users to choose for their daily operations. The S1 E will make its debut at PMRExpo, the Europe's premier trade fair for secure, mission- and business-critical communication, taking place from November 25th to 27th, 2025, at Koelnmesse in Cologne, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251124768341/en/ Hytera New Released Licence-free Analogue Business Radio S1 E Adhering to the S Series’ signature design language, the S1 E combines a stylish, modern, and minimalist aesthetic with practical functionality. Weighing under 85g, the S1 E provides all-day wearing comfort without tugging or weighing down uniforms. Key enhancements and sta
Merck Takes Patient-Directed Approach to Bring Innovation to the Treatment of Rare Neuromuscular Disorder, Generalized Myasthenia Gravis24.11.2025 15:00:00 EET | Press release
Merck, a leading science and technology company, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for cladribine capsules for the treatment of the rare, chronic autoimmune neuromuscular disorder, generalized Myasthenia Gravis (gMG). In June 2023, the FDA granted Orphan Drug Designation for cladribine capsules for the treatment of gMG. In addition, the Company is actively collaborating with patient organizations and Ad Scientiam, a medical technology company, to support a patient-directed approach to the future management of gMG. If approved, cladribine capsules, currently being studied in the global Phase 3 MyClad trial, could become the first oral treatment for gMG, a rare autoimmune neuromuscular disorder that causes severe muscle weakness and significantly impacts patients’ lives. The FDA’s Fast Track program is designed to facilitate the development and accelerate the review of therapies for serious conditions with unmet medical needs,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom